Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data
Exclusive: Baidu, investors in talks to raise $2 billion for biotech startup - source
© Reuters. FILE PHOTO: Wworker wearing a face mask cleans the floor, near a Baidu AI robot which shows a face mask on its screen, at Baidu's headquarters in Beijing
By Yingzhi Yang and Brenda Goh
BEIJING/SHANGHAI (Reuters) - Chinese tech giant Baidu (O:BIDU) is in talks with investors to raise up to $2 billion over three years for a biotech startup, which will use AI technology to discover new drugs and diagnose diseases, a person with direct knowledge of the matter said.
A second person confirmed the startup plan.
Baidu (O:BIDU) is unlikely to be the controlling investor, the first person said. Both sources spoke on condition of anonymity, adding they did not have more details on the investment as talks were still under way.
Baidu's plans come at a time of increased investment in the healthcare sector since the outbreak of the COVID-19 pandemic, with many companies expanding into online diagnosis options to fill the gaps left by overstretched, overcrowded hospitals.
WeDoctor, backed by Tencent (HK:0700), Alibaba 's (N:BABA) healthcare arm and Ping An Good Doctor (HK:1833) have joined the fray to develop apps that offer diagnosis, prescriptions, appointment bookings, 1-hour drug delivery and insurance.
But the startup under discussion plans to focus more on such areas as drug discovery and development, and early tumor diagnosis, by mobilizing Baidu's powerful artificial intelligence (AI) technology that can perform complex computing to produce biological innovations, the sources said.
The name of the startup has not been decided, but Baidu came up with the idea as early as six months ago, one of the sources said, adding that Baidu founder and Chairman Robin Li has been personally involved in the project.
Baidu declined to comment.
Baidu open-sourced its Ribonucleic acid (RNA) prediction algorithm LinearFold this year. The tool aims to accelerate the prediction time of a virus' RNA secondary structure, which is crucial to understand a virus and develop vaccines.
The healthcare industry, especially biotechnology, has seen a flood of money flow in amid the scramble for a COVID-19 vaccine and governments seeking to fix their health systems.
The Hang Seng Healthcare Index (HSHCI) has surged about 40% over the past five months, outstripping the Hang Seng Index (HSI) that edged up more than 6% over the time.
Related Articles
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.